Last updated: 2026-09-16 10:31:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
60 Degrees Pharmaceuticals, Inc. (SXTP) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $0.86, with a market capitalisation of $3.16M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.84 to $8.62. This page covers its latest market performance, valuation, price trends and company information.
$3.16M | |
$0.86 | |
$2,076.00 | |
$0.84 | |
$0.85 | |
72.00 | |
87.11K | |
-- | |
$8.62 | |
$0.84 | |
-- | |
-- |
60 Degrees Pharmaceuticals, Inc. (SXTP) is trading at $0.86 in pre-market trading as of 2026-09-16 08:34:00, up 1.96% ($0.02) from the previous close of $0.85
Pre-market trading shows how investors are pricing SXTP before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, 60 Degrees Pharmaceuticals, Inc. (SXTP) moved from $0.92 to $0.86, representing a decline of 6.12% ($0.06).
The stock traded between $0.84 and $1.04 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 76.23 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 0.3%
SXTP is currently trading at $0.86, placing it 0.3% of the way from its 52-week low of $0.84 to its 52-week high of $8.62. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Currently, company's pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company's future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 3 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of 60 Degrees Pharmaceuticals, Inc. (SXTP) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.